Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer

• Case describes a response to sunitinib in clear cell ovarian cancer. • Discussion of unique molecular characteristics of clear cell ovarian cancers; • Practical points regarding dosing and toxicity when using sunitinib discussed.

Detalles Bibliográficos
Autores principales: Alifrangis, C, Thornton, A, Fotopoulou, C, Krell, J, Gabra, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107646/
https://www.ncbi.nlm.nih.gov/pubmed/27872893
http://dx.doi.org/10.1016/j.gore.2016.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107646/
https://www.ncbi.nlm.nih.gov/pubmed/27872893
http://dx.doi.org/10.1016/j.gore.2016.11.001

Ejemplares similares